2018 ASCO-SITC Clinical Immuno-Oncology Symposium Merit Award Winners

2018 ASCO-SITC Clinical Immuno-Oncology Symposium Merit Award Winners

Merit Awards are awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO-sponsored or cosponsored meeting and recognized for its scientific merit. For more information on the Merit Awards program or instructions on how to apply, visit us online.

The following individuals were selected for a 2018 ASCO-SITC Clinical Immuno-Oncology Symposium Merit Award:

Aanika Balaji
Johns Hopkins University School of Medicine
Abstract 138: Immune-related adverse events requiring inpatient management: Spectrum of toxicity, treatment, and outcomes.              

Rachel J. David, MD
Wilmot Cancer Institute, University of Rochester Medical Center 
Abstract 100: Immunotherapy use, outcomes, and toxicities in gastrointestinal malignancies.

Michael E. Devitt, MD
University of Virginia
Abstract 155: The effect of chemotherapy on the tumor immune microenvironment in non-small cell lung cancer (NSCLC): A single-institution retrospective analysis.

Sami Ibrahimi, MD
University of Oklahoma Health Sciences Center
Abstract 213: Effect of body mass index and albumin level on outcomes of patients receiving anti PD-1/PD-L1 therapy.

Uqba Khan, MD
St. John Hospital and Medical Center
Abstract 89: Frequency and prognostic role of tumor infiltrating lymphocytes and MMR status in advanced non-colorectal GI malignancies.

Anuhya Kommalapati, MD
University of South Carolina
Abstract 133: Characterization of progressive multifocal leukoencephalopathy (PML) in patients treated with rituximab, brentuximab and ibrutinib: A report from the Southern Oncology Network on Adverse Reactions (SONAR).

Devarati Mitra, MD, PhD
Brigham & Women's Hospital/Dana Farber Cancer Institute
Abstract 150: The prognostic significance of PDL1 expression in locally advanced non-small-cell lung cancer (LA-NSCLC) treated with definitive intent.

Sarbajit Mukherjee, MD
University of Oklahoma Health Sciences Center
Abstract 208: Efficacy of PD-1/PD-L1 therapy: Do proton pump inhibitors affect the outcome?

Abdul Rafeh Naqash, MD
Brody School of Medicine at East Carolina University
Abstract 152: Survival stratification using a baseline inflammatory physiology based scoring system in advanced non-small cell lung cancer (NSCLC) treated with anti-programmed cell death-1 (anti-PD-1) therapy.

Jesus Vera Aguilera, MD
Mayo Clinic Rochester
Abstract 186: A clinical insight into therapeutic sequence in advanced melanoma.